MRNA

Moderna Inc.

Price

$214.93

return (12m)

680.71%

p/e

-24.32

p/bv

11.34

DIVIDEND YIELD

0.00%

MRNA price

Moderna

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment MRNA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

59.80%

3 months

213.54%

1 year

680.71%

2 years

265.15%

5 years

-29.51%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals MRNA

Valuation

P/E

-24.32

Sector -3.34

Industry -3.34

P/BV

11.34

Sector 1.90

Industry 1.90

P/Revenue (PSR)

34.40

Sector 2.02

Industry 2.02

EV/EBITDA

-104.94

Sector -219.13

Industry -219.13

EV/EBIT

-96.13

Sector -48.17

Industry -48.17

P/EBITDA

-27.33

Sector -22.59

Industry -22.59

P/EBIT

-25.17

Sector -30.09

Industry -30.09

P/Total Assets

6.99

Sector 1.12

Industry 1.12

P/Net Current Assets

47.46

Sector -9.63

Industry -9.63

P/Working Capital

23.36

Sector -160.04

Industry -160.04

EPS

-7.92

Sector -1.78

Industry -1.78

BVPS

16.99

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

23.38%

Sector 41.35%

Industry 41.35%

EBITDA Margin

-473.79%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

-517.24%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

-100.00%

Sector -35.47%

Industry -35.47%

Net Profit Margins

-100.00%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.01

Sector 0.03

Industry 0.03

Profitability

ROE

-46.61%

Sector -57.36%

Industry -57.36%

ROA

-28.75%

Sector -59.44%

Industry -59.44%

ROIC

-50.80%

Sector -2,371.64%

Industry -2,371.64%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.29

Sector 2.91

Industry 2.91

Net Debt / EBITDA

6.62

Sector -22.44

Industry -22.44

Net Debt / EBIT

6.06

Sector -8.34

Industry -8.34

Net Debt / Equity

-0.67

Sector -33,201.77

Industry -33,201.77

Gross Debt / Equity

0.09

Sector -0.85

Industry -0.85

Equity/Assets

0.62

Sector 0.46

Industry 0.46

Liabilities/Assets

0.38

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

-34.49%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals MRNA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
MRNA Moderna Inc.	$214.93	669.81%	0.00%	-24.32	11.34	-46.61%	-100.00%
PFE Pfizer Inc.	$28.06	16.96%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$276.45	23.37%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.39	-31.32%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$145.36	73.18%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$159.16	-4.81%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$59.57	41.53%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$74.29	-47.23%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$413.08	44.07%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$749.56	32.05%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.87	71.58%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$936.38	24.39%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$509.93	21.08%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$237.32	52.36%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$803.49	0.77%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$40.30	51.73%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$226.46	47.00%	0.00%	38.99	1.73	4.43%	8.32%
MEDP Medpace Holdings Inc.	$616.68	16.14%	0.00%	34.69	39.30	113.29%	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

MRNA - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Moderna

Moderna Inc.

Average Investor10 user rating

4.0 (19 people)

United States

10 years

Founded: 2016

2018

Time since IPO - 8 years

1.300

Employees

Moderna, Inc. is a U.S.-based biotechnology company focused on the development of messenger RNA (mRNA)–based vaccines and therapeutics. Its platform enables the design of treatments that instruct cells to produce proteins capable of preventing or treating diseases.

The company’s model is centered on scalable, adaptable biotechnology, allowing rapid development across multiple therapeutic areas.

Core activities include:

Development of mRNA-based vaccines and therapeutics
Infectious disease and pandemic-response solutions
Oncology and personalized cancer therapies
Rare-disease and autoimmune treatments
Clinical research and biologics manufacturing

Moderna operates globally, with presence across the United States, Europe, and Asia, supported by partnerships with governments, research institutions, and healthcare organizations.

Its performance is influenced by regulatory approvals, clinical trial outcomes, R&D investment cycles, global vaccine demand, and advances in biotechnology platforms.

Moderna, Inc. is listed on the Nasdaq under the ticker MRNA.

History and Development

Moderna was founded in 2010 in Massachusetts by Derrick Rossi, Noubar Afeyan, Kenneth Chien, and Robert Langer, with the goal of advancing mRNA technology for therapeutic use.

Throughout the 2010s, the company expanded its research capabilities, built manufacturing infrastructure, and established strategic scientific partnerships.

In 2018, Moderna completed its initial public offering (IPO), marking one of the largest biotech listings at the time.

A major milestone came in 2020 with the development of its COVID-19 vaccine (mRNA-1273), which brought global recognition to mRNA technology.

Since then, the company has continued to expand its pipeline, focusing on new vaccines and therapeutic applications across multiple disease areas.

Additional Information

Moderna Inc. (United States) is listed on the Nasdaq and has a market capitalization of $76.64 billion, with shareholders equity totaling $6.76 billion.

The company employs approximately 1.300 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Moderna Inc. reported $2.23 billion in revenue, generating net income of $-3.15 billion.

Key financial metrics include a P/E ratio of -24.32, a price-to-book (P/B) ratio of 11.34, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker MRNA.

Market cap

$76.64 billion

Net worth

$6.76 billion

$6,761,000,000.00

Assets

$10.96 billion

$10,961,000,000.00

Total Shares Outstanding

398.00 million

398,000,000

Average Daily Trading Volume

$19.74 million

$19,735,529.42

Sector

Health Care

Industry

Biotechnology

MRNA

revenue by Business Segment Moderna

Revenue by Region Moderna

MRNA revenue and profits

Financial Results MRNA

DRAG THE FRAME TO SEE MORE DATA

MRNA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$936.38 23,12% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$237.32 53,22% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$276.45 23,76% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$145.36 74,00% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$159.16 --4,21% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$28.06 21,21% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$59.57 43,39% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$936.38 23,12% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$237.32 53,22% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$276.45 23,76% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$145.36 74,00% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$159.16 --4,21% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$28.06 21,21% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$59.57 43,39% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of Moderna (MRNA) today?

The current price of Moderna (MRNA) is $214.93. The stock began the year trading around $29.49 and is currently priced at $214.93. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Moderna (MRNA) pay dividends?

Moderna (MRNA) did not pay dividends over the past year.

Is Moderna (MRNA) a good investment?

Moderna (MRNA) is currently trading at $214.93 with a P/E ratio of -24.32. This represents a -650% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 680.71%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Moderna (MRNA) stock?

You can buy Moderna (MRNA) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol MRNA and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Moderna (MRNA) yield today?

Over the past month, Moderna (MRNA) has returned 59.80% — 680.71% over the past year, and -29.51% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Moderna (MRNA) today at the current price of $214.93 your total investment would be $21,493.00.

Based on historical performance, the investment would have grown to approximately:

$167,798.00 after 1 year
$15,150.42 after 5 years
$21,493.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

MRNA

Moderna Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment MRNA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING MRNA WITH OTHER STOCK

ABOUT Moderna

Moderna Inc.

United States

10 years

2018

1.300

History and Development

Additional Information

PROFIT X PRICE MRNA

Financial Results MRNA

MRNA cash flow

Asset, Revenue and Profit Growth - MRNA

MRNA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions